NCT02346201
Apathy in Dementia Methylphenidate Trial 2
See it on ClinicalTrials.gov ↗199 people
34.2%
65.8%
68 womenmiddle line = equal numbers131 men
- Phase
- PHASE3
- Paid for by
- Johns Hopkins Bloomberg School of Public Health
- Finished
- 2020-07-15
- Health conditions
- Apathy, Alzheimer's Disease
- Who could join
- Anyone
- Ages
- no minimum – no maximum
- Average age
- median 76 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 91% · Black / African American 6% · Other 2.5% · Not reported 0.5% · American Indian / Alaska Native 0% · Asian 0% · Native Hawaiian / Pacific Islander 0% · More than one race 0%
Women left out
- No women who could get pregnant
Most women roughly 15–50 years old were turned away.
“Women with childbearing potential”
- Only women past menopause
Women who could still get pregnant were turned away.
“If female, woman must be post-menopausal for at least 2 years or have had a hysterectomy”
- No seizures
Women with epilepsy or past seizures were turned away.
“Central nervous system abnormalities (e.g., cerebral aneurysm), seizures (convulsions, epilepsy), Tourette's syndrome or presence of motor tics, or abnormal electroencephalograms”
- No mental health conditions
Women with depression, bipolar disorder or other mental health conditions were turned away.
“Currently meets criteria for Major Depressive Episode, by Diagnostic Statistical Manual of Mental Disorder - IV (TR) criteria”
Study titles and rules are shown in their original English.